These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 15834926

  • 1. Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide.
    Hoskin PJ, Rojas AM, Phillips H, Saunders MI.
    Cancer; 2005 Jun 01; 103(11):2287-97. PubMed ID: 15834926
    [Abstract] [Full Text] [Related]

  • 2. Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: mature results of a Phase II nonrandomized study.
    Hoskin P, Rojas A, Saunders M.
    Int J Radiat Oncol Biol Phys; 2009 Apr 01; 73(5):1425-31. PubMed ID: 19036531
    [Abstract] [Full Text] [Related]

  • 3. Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck.
    Hoogsteen IJ, Pop LA, Marres HA, Merkx MA, van den Hoogen FJ, van der Kogel AJ, Kaanders JH.
    Int J Radiat Oncol Biol Phys; 2006 Jan 01; 64(1):83-9. PubMed ID: 16213107
    [Abstract] [Full Text] [Related]

  • 4. Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide.
    Hoskin PJ, Saunders MI, Dische S.
    Cancer; 1999 Oct 01; 86(7):1322-8. PubMed ID: 10506720
    [Abstract] [Full Text] [Related]

  • 5. Carbogen and nicotinamide in locally advanced bladder cancer: early results of a phase-III randomized trial.
    Hoskin PJ, Rojas AM, Saunders MI, Bentzen SM, Motohashi KJ, BCON investigators.
    Radiother Oncol; 2009 Apr 01; 91(1):120-5. PubMed ID: 18992952
    [Abstract] [Full Text] [Related]

  • 6. ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for research and treatment of cancer (EORTC).
    Bernier J, Denekamp J, Rojas A, Minatel E, Horiot J, Hamers H, Antognoni P, Dahl O, Richaud P, van Glabbeke M, Piérart M.
    Radiother Oncol; 2000 May 01; 55(2):111-9. PubMed ID: 10799722
    [Abstract] [Full Text] [Related]

  • 7. Acute toxicity profile and compliance to accelerated radiotherapy plus carbogen and nicotinamide for clinical stage T2-4 laryngeal cancer: results of a phase III randomized trial.
    Janssens GO, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, Chin A, Pop LA, Kaanders JH.
    Int J Radiat Oncol Biol Phys; 2012 Feb 01; 82(2):532-8. PubMed ID: 21300447
    [Abstract] [Full Text] [Related]

  • 8. Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer.
    Koukourakis MI, Tsolos C, Touloupidis S.
    Urology; 2007 Feb 01; 69(2):245-50. PubMed ID: 17320657
    [Abstract] [Full Text] [Related]

  • 9. Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide.
    Saunders M, Dische S.
    Br J Cancer Suppl; 1996 Jul 01; 27():S271-8. PubMed ID: 8763896
    [Abstract] [Full Text] [Related]

  • 10. Radiotherapy alone or combined with carbogen breathing for squamous cell carcinoma of the head and neck: a prospective, randomized trial.
    Mendenhall WM, Morris CG, Amdur RJ, Mendenhall NP, Siemann DW.
    Cancer; 2005 Jul 15; 104(2):332-7. PubMed ID: 15937906
    [Abstract] [Full Text] [Related]

  • 11. Toxicity and outcome of a phase II trial of taxane-based neoadjuvant chemotherapy and 3-dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer.
    Rojas AM, Lyn BE, Wilson EM, Williams FJ, Shah N, Dickson J, Saunders MI.
    Cancer; 2006 Sep 15; 107(6):1321-30. PubMed ID: 16902985
    [Abstract] [Full Text] [Related]

  • 12. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial.
    Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, Chin A, Marres HA, de Bree R, van der Kogel AJ, Hoogsteen IJ, Bussink J, Span PN, Kaanders JH.
    J Clin Oncol; 2012 May 20; 30(15):1777-83. PubMed ID: 22508814
    [Abstract] [Full Text] [Related]

  • 13. Early complications and survival following short-term palliative radiotherapy in invasive bladder carcinoma.
    Holmäng S, Borghede G.
    J Urol; 1996 Jan 20; 155(1):100-2. PubMed ID: 7490801
    [Abstract] [Full Text] [Related]

  • 14. A randomised trial of accelerated radiotherapy for localised invasive bladder cancer.
    Horwich A, Dearnaley D, Huddart R, Graham J, Bessell E, Mason M, Bliss J.
    Radiother Oncol; 2005 Apr 20; 75(1):34-43. PubMed ID: 15878099
    [Abstract] [Full Text] [Related]

  • 15. Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy.
    Cowan RA, McBain CA, Ryder WD, Wylie JP, Logue JP, Turner SL, Van der Voet J, Collins CD, Khoo VS, Read GR.
    Int J Radiat Oncol Biol Phys; 2004 May 01; 59(1):197-207. PubMed ID: 15093917
    [Abstract] [Full Text] [Related]

  • 16. A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder.
    Harland SJ, Kynaston H, Grigor K, Wallace DM, Beacock C, Kockelbergh R, Clawson S, Barlow T, Parmar MK, Griffiths GO, National Cancer Research Institute Bladder Clinical Studies Group.
    J Urol; 2007 Sep 01; 178(3 Pt 1):807-13; discussion 813. PubMed ID: 17631326
    [Abstract] [Full Text] [Related]

  • 17. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M, Study Group for Therapies of Rectal Malignancies (STORM).
    Int J Radiat Oncol Biol Phys; 2006 Mar 15; 64(4):1129-39. PubMed ID: 16414206
    [Abstract] [Full Text] [Related]

  • 18. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer.
    Chung PW, Bristow RG, Milosevic MF, Yi QL, Jewett MA, Warde PR, Catton CN, McLean M, Moore M, Tannock IF, Gospodarowicz MK.
    Urol Oncol; 2007 Mar 15; 25(4):303-9. PubMed ID: 17628296
    [Abstract] [Full Text] [Related]

  • 19. The case for radiotherapy with or without chemotherapy in high-risk superficial and muscle-invading bladder cancer.
    Zietman AL, Shipley WU, Heney NM, Althausen AF.
    Semin Urol Oncol; 1997 Aug 15; 15(3):161-8. PubMed ID: 9394911
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group.
    Gogna NK, Matthews JH, Turner SL, Mameghan H, Duchesne GM, Spry N, Berry MP, Keller J, Tripcony L, Trans Tasman Radiation Oncology Group.
    Radiother Oncol; 2006 Oct 15; 81(1):9-17. PubMed ID: 17011058
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.